Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Breast tumors generally consist of a diverse population of cells with varying gene expression
profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …

Highlights•SpyTag and SpyCatcher are peptide–protein partners that lock together
covalently.•Reaction occurs in a wide range of protein contexts, buffers and …

Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active
cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic …